Cartesian Therapeutics
RNAC
48 hedge funds and large institutions have $235M invested in Cartesian Therapeutics in 2017 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 3 reducing their positions, and 7 closing their positions.
800% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 3
340% more capital inflows, than outflows
Capital inflows: $61.1M | Capital outflows: $13.9M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
16.88% more ownership
Funds ownership: 46.7% → 63.58% (+17%)
4% more funds holding
Funds holding: 46 → 48 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vivo Capital
Palo Alto,
California
|
+$16.5M |
| 2 |
Great Point Partners
Greenwich,
Connecticut
|
+$13.8M |
| 3 |
Perceptive Advisors
New York
|
+$9.7M |
| 4 |
BlackRock
New York
|
+$4.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Flagship Pioneering
Cambridge,
Massachusetts
|
-$11.8M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.02M |
| 3 |
Goldman Sachs
New York
|
-$452K |
| 4 |
Hikari Power
Tokyo,
Japan
|
-$349K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$192K |
RNAC Hedge Fund Activity: Q2 2017 in Review
48 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q2 2017, worth a combined $235M — up 90% from $124M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new RNAC positions and 7 closed out — a net gain of 2 holders — while 27 added to existing stakes and 3 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $16.5M. The largest seller was Flagship Pioneering, exiting entirely with an estimated $11.8M sold.
- 48 institutional investors held Cartesian Therapeutics (RNAC) as of Q2 2017, up from 46 in Q1 2017.
- Funds reported $235M of Cartesian Therapeutics stock for Q2 2017, up 90% quarter-over-quarter.
- 9 funds opened new Cartesian Therapeutics positions in Q2 2017 and 7 closed out, a net change of +2 holders.
- The largest Cartesian Therapeutics buyer in Q2 2017 was Vivo Capital, an estimated $16.5M added.
- The largest Cartesian Therapeutics seller in Q2 2017 was Flagship Pioneering, an estimated $11.8M sold.
Based on aggregated 13F filings for Q2 2017.